Glinks Law Firm

Founded in 2007, Glinks law firm has around 80 lawyers with a focus on compliance, maritime regulatory, international trade, investment, M&A, IP and capital markets.

The firm represented an A-share and H-share dual-listed pharmaceutical company in a dispute over the foreign registration of a biosimilar. This case is China’s first cross-border biosimilar registration billion-RMB level dispute.

Notable clients include China State Shipbuilding Corporation, Shanghai Zhenhua Port Machiner Company, China Railway Engineering Group and American International Group AIG.